Format

Send to

Choose Destination
Cephalalgia. 2014 Jun;34(7):523-32. doi: 10.1177/0333102413515348. Epub 2013 Dec 11.

A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.

Author information

1
Norwegian National Headache Centre, Department of Neuroscience, Norwegian University of Science and Technology (NTNU), and St. Olavs Hospital, Norway lars.stovner@ntnu.no.
2
Norwegian National Headache Centre, Department of Neuroscience, Norwegian University of Science and Technology (NTNU), and St. Olavs Hospital, Norway.
3
Norwegian National Headache Centre, Department of Neuroscience, Norwegian University of Science and Technology (NTNU), and St. Olavs Hospital, Norway Department of Neurology, Oslo University Hospital - Rikshospitalet, Norway.

Abstract

OBJECTIVE:

The objective of this article is to see whether the effect of candesartan for migraine prevention, shown in one previous study, could be confirmed in a new study, and if so, whether the effect was comparable to that of propranolol (non-inferiority analysis), and whether adverse events were different.

METHODS:

In a randomised, triple-blind, double cross-over study, 72 adult patients with episodic or chronic migraine went through three 12-week treatment periods on either candesartan 16 mg, propranolol slow-release 160 mg, or placebo. The main outcome measures were days with migraine headache per four weeks (primary outcome), days with headache, hours with headache, proportion of responders (>50% reduction of migraine days from baseline), and adverse events.

RESULTS:

In the modified intention-to treat-analysis, candesartan and propranolol were both superior to placebo: 2.95 (95% confidence interval: 2.35-3.55%) and 2.91 (2.36-3.45%), versus 3.53 (2.98-4.08%) for migraine days per month (p = 0.02 for both comparisons, Wilcoxon's paired signed rank test, blinded statistical analysis). Candesartan was non-inferior to propranolol (and vice versa). The proportion of responders was significantly higher on candesartan (43%) and propranolol (40%) than on placebo (23%) (p = 0.025 and <0.050, respectively). There were more adverse events on candesartan (n = 133%) and propranolol (n = 143%) than on placebo (n = 90%), and the adverse event profiles of the active substances differed somewhat.

CONCLUSION:

It is confirmed that candesartan 16 mg is effective for migraine prevention, with an effect size similar to propranolol 160 mg, and with somewhat different adverse events.

TRIAL REGISTRATION:

EUDRACT (2008-002312-7), ClinicalTrials.gov (NCT00884663).

KEYWORDS:

Candesartan; clinical trial; migraine; prophylaxis; propranolol

PMID:
24335848
DOI:
10.1177/0333102413515348
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center